Posted by Michael Wonder on 08 Nov 2022
Blue Earth Therapeutics awarded UK MHRA innovation passport for investigational 177Lu-rhPSMA-10.1 for treatment of metastatic castrate-resistant prostate cancer
8 November 2022 - Lutetium LU 177 labeled radiohybrid prostate specific membrane antigen (Lu 177-rhPSMA-10.1) is an optimised therapeutic radiopharmaceutical.
Blue Earth Therapeutics today announced that its investigational therapeutic radiopharmaceutical, Lutetium Lu 177-rhPSMA-10.1, has been awarded an Innovation Passport for the treatment of metastatic castrateresistant prostate cancer.
